Skip to main content
. 2023 May 31;30(2):167–177. doi: 10.11005/jbm.2023.30.2.167

Table 5.

Differences between patients with or without osteoporosis or bone microarchitecture degradation

Variables With osteoporosis or bone microarchitecture degradation Without osteoporosis or bone microarchitecture degradation


Sample (N=109) Osteoporosis (T-score ≤−2.5) P-value Sample (N=57) Bone degradation (TBS <1.230) P-value


Yes (N=17) No (N=92) Yes (N=13) No (N=44)
Age (yr) 58.0 (53.0–61.0) 59.0 (53.5–63.5) 57.0 (53.0–61.0) 0.128a) 58.0 (54.0–61.5) 59.0 (57.0–63.5) 57.5 (53.0–61.0) 0.107a)

Length of hospital stay (days) 20.0 (11.0–32.0) 24.0 (10.0–44.8) 20.0 (11.0–31.0) 0.247a) 22.0 (12.0–34.0) 32.5 (14.0–36.5) 20.0 (11.0–33.0) 0.182a)

HbA1c (%) 6.4 (5.8–8.4) 6.1 (5.7–7.2) 6.5 (5.8–8.8) 0.316a) 6.4 (5.9–8.3) 6.4 (5.7–8.3) 6.3 (5.9–8.3) 0.739a)

eGFR (mL/min/1.73 m2) 78.1 (47.5–97.7) 89.9 (48.2–100.4) 73.0 (45.3–96.9) 0.381a) 79.8 (58.0–100.0) 60.5 (31.7–95.7) 86.4 (60.7–100.0) 0.159a)

25(OH)D (ng/mL) 23.1 (17.8–30.7) 21.6 (15.1–28.6) 23.1 (18.1–30.8) 0.659a) 22.3 (18.1–27.1) 19.1 (15.1–29.4) 22.6 (18.5–26.4) 0.610a)

PTH (pg/mL) 36.0 (26.5–63.2) 62.5 (37.2–119.0) 34.2 (25.0–54.1) 0.016a) 30.9 (24.0–54.2) 44.3 (33.4–104.0) 28.0 (21.2–49.8) 0.024a)

LVEF (%) 48.0 (34.0–60.0) 31.0 (25.0–60.0) 48.0 (35.3–60.0) 0.086a) 54.0 (34.0–60.5) 40.0 (30.0–57.5) 56.0 (34.3–61.8) 0.313a)

BMI (kg/m2) 28.3±5.4 23.2±4.4 29.2±5.0 <0.001b) 28.6±5.4 27.6±4.8 28.9±5.6 0.443b)

TBS 1.362 (1.261–1.431) 1.201 (1.063–1.279) 1.368 (1.293–1.435) 0.013a)

T-score LS −0.867±1.587 −2.015±1.520 −0.527±1.455 0.002b)

T-score FN −0.895±1.163 −1.654±1.124 −0.670±1.088 0.006b)

T-score TF −0.400±1.291 −1.131±1.447 −0.113±1.160 0.011b)
a)

Mann–Whitney U test.

b)

Student’s t-test.

HbA1c, hemoglobin A1c; eGFR, estimated glomerular filtration rate; 25(OH)D, 25-hydroxy-vitamin D; PTH, parathyroid hormone; LVEF, left ventricular ejection fraction; BMI, body mass index; TBS, trabecular bone score; LS, lumbar spine; FN, femoral neck; TF, total femur.